immunogenicity | pharmaphorum

Skip to main content

Friday 9 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

immunogenicity

R&D

2nd LNP Immunogenicity & Toxicity Summit

Partner Content

2nd LNP Immunogenicity & Toxicity Summit

Back for its second iteration, the LNP Immunogenicity & Toxicity Summit (December 11-13, 2023 | Boston) will bring together 1

Views & Analysis

vaccines

Overcoming the challenges of developing vaccines in an accel...

The COVID-19 pandemic stopped the world in its tracks.

Events

pharmaphorum (3)

Partner Content

2nd Gene Therapy Immunogenicity

Modulate, Measure & Predict Immune Response to GTx

Partner Content

C&GT

Partner Content

A Run Down of Keynote Sessions for Cell & Gene Therapy 2...

Cell and Gene Therapy

Partner Content

Immuno-Oncology

Partner Content

Immuno-Oncology challenges include identifying patients befo...

Challenges facing Immuno-Oncology industry

Events

640x360 Biosimilars USA

Partner Content

SMi's 5th Annual Biosimilars USA Conference

Biosimilars USA conference information

Load more results

Editor's Picks

AbbVie's Cerevel takeover delivers Parkinson's approval

FDA clears first drug for MCT8 deficiency

Novartis taps China's Abogen for autoimmunity TCE

AZ takes stake in Summit Therapeutics in $2bn deal

PhRMA hires ex-House Majority Leader Eric Cantor as its CEO

News

argenx's Forte acquisition delivers coeliac trial win

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company